Venus Medtech (Hangzhou), Inc. Class H (HK:2500) has released an update.
Venus Medtech (Hangzhou) Inc. has announced the successful first patient implantation in the U.S. of its VenusP-Valve as part of a pivotal clinical trial, potentially positioning the Chinese heart valve system among global market leaders. The VenusP-Valve has already been registered and marketed in over 50 countries and has been included in national health insurance programs in countries such as Germany and France. Despite the promising international clinical progress of VenusP-Valve, the company’s shares remain suspended on the Hong Kong Stock Exchange since November 2023.
For further insights into HK:2500 stock, check out TipRanks’ Stock Analysis page.
